Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports 2021

Analyst Reports 2021
September 20th 2021

Maxim Group - The Case for LAG-3 is Building

August 30th 2021

Maxim Group - Annual FY Update; AIPAC Final Data Approaching

July 16th 2021

Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 TP

July 14th 2021

Bell Potter - Creating Value with Phase 3 around the corner – Increasing TP to AUD 1.00 (from AUD 0.85)

July 6th 2021

goetzpartners securities -LAG-3 therapies taking immunology to the next level - Increasing TP to AUD 1.35 (from AUD 1.24)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

July 6th 2021

Taylor Collison - Efti development program expanded - Increasing TP to AUD 1.19 (from AUD 0.85)

For a copy of this research report please contact your Taylor Collison advisor.

June 10th 2021

Alliance Global Partners - Immutep's Vindication and the Next Chapter in LAG-3 Immunotherapy — increasing to US$9 (from US$6)

June 5th 2021

goetzpartners securities - Efti combos move towards centre stage at ASCO : Increasing TP to A$1.24 (from A$0.90)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

June 4th 2021

Maxim Group - ASCO Updates, LAG-3 is Emerging – Shares Remain Undervalued

May 20th 2021

goetzpartners securities - BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

May 3rd 2021

Corporate Connect - Efti a highly sought after compound for mono & combo Cancer treatment

April 9th 2021

Bell Potter - Efti granted Fast Track - A vote of confidence (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

April 8th 2021

Alliance Global Partners - FDA's Fast Track for Efti Suggests Regulators Echo Large Pharma Enthusiasm Surrounding LAG-3 Immunotherapy

March 31st 2021

Bell Potter - Validation for LAG-3 arrives (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

March 25th 2021

goetzpartners securities - BMS Study Identifies LAG-3 - PD-1 as Potential 'Key Strategy'

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

March 25th 2021

Maxim Group - Bristol Brings LAG-3 to the Forefront in Checkpoints with First Positive P3 Trial; Bodes Well for Efti and LAG-3 Pipeline

March 16th 2021

goetzpartners securities - Targeting first-line head and neck with Merck & Co

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

March 16th 2021

Maxim Group - Success in 2L H&N Cancer Leads to Second Collaboration to Move into 1L – Reiterate Buy

March 5th 2021

Bell Potter - Stage 2 of 2nd line NSCLC patient cohort in Phase 2 TACTI-002 trial starts recruitment (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

February 25th 2021

Bell Potter - 1H21 Results broadly in-line (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

February 5th 2021

Bell Potter - Strong balance sheet with several catalysts (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

January 26th 2021

Alliance Global Partners - Raising PT to $6 from $5; MBC Program Thrown a Lifeline by OS Data as IMMP Shares Find Their Heading for the Year of the Sea Shanty